Received: 4 June 2021
Accepted: 7 November 2021
First Online: 24 November 2021
: The local Institutional Review Board approved the retrospective chart review. The study was conducted in compliance with the declaration of Helsinki, US Code of Federal Regulations Title-21, and the Harmonized Tripartite Guidelines for Good Clinical Practice (1996). A inform consent waiver was obtained as this was a retrospective chart review.
: Not applicable.
: QDN is a recipient of a Physician Scientist Award from Research to Prevent Blindness, New York, NY, and serves on the Scientific Advisory Board for AbbVie, Bayer, Genentech, Regeneron, and Santen, among others. QDN also chaired the Steering Committee for the RISE and RIDE studies and was on the Steering Committee for the VISTA Study, and other studies sponsored by Genentech and Regeneron.